This company is based in France. This is the contact point for companies in France looking to out source production to accredited and approved sites in India. Medreich sites have been audited by Affsaps. We already manufacture for 2 well known French companies for their domestic market. Medreich France also coordinates the sale of Medreich brands into Francophone Africa and the Mahgreb through its associated pharmaceutical field force and promotion company. About 50 sales representative are available to promote pharmaceutical products for principals throughout French West Africa, the Mahgreb including Algeria as well as Madagaskar and Vietnam.

The management of Medreich France have been closely involved with the French market for over thirty years, having worked for a number of companies including multinational companies in France. They maintain an impressive network of key contacts and customers that could be accessed by any company really interested in exploring the French market or the export market via France.

This manufacturing site for cephalosporin injections is part of the Medreich Group of Companies. Products are sold widely in Europe with the largest single markets being France, the Middle East and Asia. The main products are ceftriaxone, ceftazadime and other cephalosporin injections.

New expansion plans are being explored to introduce new products into the market for existing and new customers. The factory in Spain has been there for over twenty years and there is a loyal customer base around the world, including now customers in the CIS and Russia.

This is the International Headquarters of the Group outside India. The office is fully staffed with a team covering sales and marketing, regulatory, logistics and finance and administration. The office co-ordinates all sales and business development in the European and African markets as well as the Middle East. The office is also the hub for all the global subsidiaries.

Since we are based in the UK, the main focus is to build a strong business in the UK by expanding the Intellectual Property. Medreich started its business in the UK as a contract manufacturer in 1999. As time has gone on, Medreich has bought licences, and even filed its own dossiers in the UK. Now we have over thirty licenses, which are being actively used to sell Medreich products in the UK, either in our own livery or in the livery of some of the key leading generic distributors in the market. The business is growing and as a result the regulatory team is expanding to manage the licence base.

One of the key platforms for future growth will come from the in-house ability to file dossiers. Where Medreich sees niche opportunities, dossiers are under development with a view to offer something extra to key customers in the market going forward. At least ten R and D projects are currently underway for the UK market alone. The dossiers delivered now will be fast to register as they will be current state of the art in terms of ready to file applications.

Nigeria remains one of the key markets for Medreich brands. Medreich has been a force in Nigeria for over 15 years and is a well known company with some of the most respected brands on the market. Fleming, Ibex, Reichlox, Malareich, Artrin, Zoxon and Axacef are all leading brands on the market. The company runs a large sales and marketing team and distributes the products nationwide through a strong distribution network.

The company also manufactures a number of leading brands for GSK for this market.

South Africa is a key market for the Group. The primary strategy here is manufacturing for one of the largest healthcare groups in the country, Adcock Ingram. A few billion units are manufactured and shipped to South Africa each year. The products are manufactured mainly in a jointly owned facility in India called Adcock Ingram (India) Limited, part of the Medreich Group of companies.

After over 5 years of contrat manufacturing for Adcock Ingram by Medreich, Adcock understood the real strengths of the Medreich organisation in manufacturing and partnering; and the Joint venture in India quickly became a reality with one of the largest and most impressive manufacturing sites in India.

The focus is on automation and handling large production runs. However the need to manage complexity has not been lost. There is the ability to pack in all types of packaging from pvc blisters to alu-alu formats and tropicalised packaging, and to handle multiple different packing operations at the same time, with over ten packing lines running in parallel.

The facility was recently audited earlier in 2009 by TGA and found to be performing well and to the required standards.

This company pioneered Medreich's entry into Asia. The company has regional responsibility for all the sales in Asia. There is a field force in Hong Kong where some brands have started to build strong positions in the market, notably Fleming and Axacef. Other markets managed from here include Macao, Malaysia, Singapore, Malaysia and Taiwan. The company believes there is a huge potential for future growth in Asia, and this company is our footprint on the ground, to build the partnerships we need for the future. Asia will be a huge engine of growth in the next decade, and not just because of the powerhouse in China and its active pharmaceutical ingrendients.

This company in really a distributor and it has grown a lot in recent years with its strong management team. Medreich products account for a small percentage of the total sales. Macao is often seen as a stone's throw to China, and this could be the next natural step to take to growing the business in the Region.

This company is a successful distributor in Singapore supplying a range of otc and nutritional products as well as other brands.

About 5 years ago Medreich ventured into the Australian market. Three of our plants have been audited and approved on a number of occasions by the TGA. We have been able to develop our own dossiers for these markets, and a number of registrations have been granted and more are in the pipeline. The business continues to grow and substantial progress has been made in the supply of a range of OTC and nutritional products to the Australian market.

Although still relatively small, the local management team maintain one of the best networks of contacts in the market, from GSK, Alphapharm to Pharmacare, from api suppliers to the otc segment to ethicals and nutritionals. This is a space to watch for the future growth of Medreich in the Region and for the company.